

One year of liraglutide treatment offers sustained and more weight reduction compared with sitagliptin, both in patients with type 2 diabetes: a randomised, parallel-gr

International Journal of Clinical Practice

65, 397-407

DOI: [10.1111/j.1742-1241.2011.02656.x](https://doi.org/10.1111/j.1742-1241.2011.02656.x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Tailoring treatment for type 2 diabetes: Uncovering the HOW and NOW of GLP-1 receptor agonist therapy. <i>Osteopathic Family Physician</i> , 2011, 3, 217-236.	0.2	1
2	Liraglutide Narrows the Range of Circadian Glycemic Variations in Japanese Type 2 Diabetes Patients and Nearly Flattens These Variations in Drug-Naive Type 2 Diabetes Patients: A Continuous Glucose Monitoring-Based Study. <i>Diabetes Technology and Therapeutics</i> , 2011, 13, 1139-1144.	2.4	29
3	Liraglutide. <i>Drugs</i> , 2011, 71, 2347-2373.	4.9	36
5	Glucagon like-peptide 1 receptor and the liver. <i>Liver International</i> , 2011, 31, 1243-1245.	1.9	10
6	Beyond Metformin: Initiating Combination Therapy in Patients with Type 2 Diabetes Mellitus. <i>Pharmacotherapy</i> , 2011, 31, 44S-53S.	1.2	16
7	The efficacy and safety of liraglutide. <i>International Journal of Clinical Pharmacy</i> , 2011, 33, 740-749.	1.0	16
9	The Pharmacologic Basis for Clinical Differences among GLP-1 Receptor Agonists and DPP-4 Inhibitors. <i>Postgraduate Medicine</i> , 2011, 123, 189-201.	0.9	28
10	Next-Generation GLP-1 Therapy: An Introduction to Liraglutide. <i>Postgraduate Medicine</i> , 2011, 123, 239-247.	0.9	4
11	Patient preferences for diabetes management among people with type 2 diabetes in Denmark – a discrete choice experiment. <i>Current Medical Research and Opinion</i> , 2011, 27, 2175-2183.	0.9	60
12	The Influence of Incretin Mimetics on Cardiovascular Risk Factors in Diabetes. <i>Isrn Endocrinology</i> , 2012, 2012, 1-5.	2.0	4
13	Glucagon-Like Peptide-1 and Diabetes 2012. <i>Experimental Diabetes Research</i> , 2012, 2012, 1-1.	3.8	4
14	Choosing GLP-1 Receptor Agonists or DPP-4 Inhibitors: Weighing the Clinical Trial Evidence. <i>Clinical Diabetes</i> , 2012, 30, 3-12.	1.2	24
15	Cardiovascular protective properties of incretin-based therapies in type 2 diabetes. <i>Current Opinion in Lipidology</i> , 2012, 23, 540-547.	1.2	13
16	What Have We Learned About the Treatment of Type 2 Diabetes? The Evolving Paradigms. <i>American Journal of Therapeutics</i> , 2012, 19, 449-464.	0.5	3
17	Pancreatitis: A Potential Complication of Liraglutide?. <i>Annals of Pharmacotherapy</i> , 2012, 46, 1547-1553.	0.9	26
18	Current treatments and strategies for type 2 diabetes: Can we do better with GLP-1 receptor agonists?. <i>Annals of Medicine</i> , 2012, 44, 338-349.	1.5	10
19	GLP-1 receptor agonists: A clinical perspective on cardiovascular effects. <i>Diabetes and Vascular Disease Research</i> , 2012, 9, 95-108.	0.9	78
20	Efficacy and Safety of Switching From the DPP-4 Inhibitor Sitagliptin to the Human GLP-1 Analog Liraglutide After 52 Weeks in Metformin-Treated Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2012, 35, 1986-1993.	4.3	58

#	ARTICLE	IF	CITATIONS
21	Managing Diabetes in Patients With Diabetes of Long Duration. <i>The Diabetes Educator</i> , 2012, 38, 23S-30S.	2.6	2
22	Impact of GLP-1 Receptor Agonists on Major Gastrointestinal Disorders for Type 2 Diabetes Mellitus: A Mixed Treatment Comparison Meta-Analysis. <i>Experimental Diabetes Research</i> , 2012, 2012, 1-14.	3.8	37
23	Effects of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight: A Meta-Analysis. <i>Experimental Diabetes Research</i> , 2012, 2012, 1-8.	3.8	79
25	Design, findings and implications of the liraglutide Phase III clinical trial program. <i>Clinical Investigation</i> , 2012, 2, 59-72.	0.0	4
26	Recent advances in incretin-based therapies. <i>Clinical Endocrinology</i> , 2012, 77, 489-499.	1.2	58
27	Metformin + saxagliptin for type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 139-146.	0.9	16
28	Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis. <i>Journal of Medical Economics</i> , 2012, 15, 28-37.	1.0	24
29	DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials. <i>Diabetes and Metabolism</i> , 2012, 38, 89-101.	1.4	157
30	Glucagon-like peptide-1 inhibits insulinotropic effects of oxyntomodulin and glucagon in cattle. <i>Domestic Animal Endocrinology</i> , 2012, 42, 155-164.	0.8	6
31	Dipeptidylpeptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) receptor agonists: Yes. <i>European Journal of Internal Medicine</i> , 2012, 23, 126-131.	1.0	22
32	Dipeptidyl peptidase-4 (DPP-4) inhibitors are favourable to Glucagon-Like Peptide-1 (GLP-1) agonists: No. <i>European Journal of Internal Medicine</i> , 2012, 23, 132-136.	1.0	15
33	Cardiovascular Biology of the Incretin System. <i>Endocrine Reviews</i> , 2012, 33, 187-215.	8.9	468
34	Incretin therapy and its effect on body weight in patients with diabetes. <i>Primary Care Diabetes</i> , 2012, 6, 187-191.	0.9	15
35	Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. <i>BMJ: British Medical Journal</i> , 2012, 344, e1369-e1369.	2.4	356
36	Comparison of efficacy between incretin-based therapies for type 2 diabetes mellitus. <i>BMC Medicine</i> , 2012, 10, 152.	2.3	20
37	Incretin-based therapies for type 2 diabetes. <i>Practice Nursing</i> , 2012, 23, 508-515.	0.1	0
38	Incretin therapies for type 2 diabetes: what nurses need to know. <i>NursePrescribing</i> , 2012, 10, 345-352.	0.1	0
39	Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2012, 37, 510-524.	0.7	36

#	ARTICLE	IF	CITATIONS
40	Therapeutic choices, and the nurse practitioner's role, in type 2 diabetes when metformin alone is no longer enough. <i>Journal of the American Academy of Nurse Practitioners</i> , 2012, 24, 234-248.	1.4	3
41	The design of the liraglutide clinical trial programme. <i>Diabetes, Obesity and Metabolism</i> , 2012, 14, 4-12.	2.2	9
42	Liraglutide in oral antidiabetic drug combination therapy. <i>Diabetes, Obesity and Metabolism</i> , 2012, 14, 13-19.	2.2	14
43	Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents. <i>Diabetes, Obesity and Metabolism</i> , 2012, 14, 20-32.	2.2	29
44	Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide. <i>Diabetes, Obesity and Metabolism</i> , 2012, 14, 41-49.	2.2	24
45	Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2012, 14, 882-892.	2.2	49
46	Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus. <i>Diabetology and Metabolic Syndrome</i> , 2012, 4, 8.	1.2	18
47	DPP-4 Inhibitors and Lipids: Systematic Review and Meta-Analysis. <i>Advances in Therapy</i> , 2012, 29, 14-25.	1.3	185
48	A Retrospective, Case-Note Survey of Type 2 Diabetes Patients Prescribed Incretin-Based Therapies in Clinical Practice. <i>Diabetes Therapy</i> , 2013, 4, 27-40.	1.2	37
49	Current Issues in Glp-1 Receptor Agonist Therapy for Type 2 Diabetes. <i>Endocrine Practice</i> , 2013, 18, 6-26.	1.1	6
50	Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction. <i>International Journal of Clinical Pharmacy</i> , 2013, 35, 159-172.	1.0	58
51	Is there a place for incretin therapies in obesity and prediabetes?. <i>Trends in Endocrinology and Metabolism</i> , 2013, 24, 145-152.	3.1	38
53	One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target. <i>Journal of Diabetes and Its Complications</i> , 2013, 27, 492-500.	1.2	42
54	Cardiovascular Effects of Incretins in Diabetes. <i>Canadian Journal of Diabetes</i> , 2013, 37, 309-314.	0.4	20
55	Retrospective Real-World Adherence in Patients With Type 2 Diabetes Initiating Once-Daily Liraglutide 1.8 mg or Twice-Daily Exenatide 10 ¼g. <i>Clinical Therapeutics</i> , 2013, 35, 795-807.	1.1	40
56	Options for Combination Therapy in Type 2 Diabetes: Comparison of the ADA/EASD Position Statement and AACE/ACE Algorithm. <i>American Journal of Medicine</i> , 2013, 126, S10-S20.	0.6	67
57	The cardiovascular safety of incretin-based therapies: a review of the evidence. <i>Cardiovascular Diabetology</i> , 2013, 12, 130.	2.7	36
58	GLP-1 Receptor Agonists: Effects on Cardiovascular Risk Reduction. <i>Cardiovascular Therapeutics</i> , 2013, 31, 238-249.	1.1	63

#	ARTICLE	IF	CITATIONS
59	Extraglycemic effects of glp-1-based therapeutics: Addressing metabolic and cardiovascular risks associated with type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2013, 100, 1-10.	1.1	40
60	Enhancing treatment success with incretin-based therapies: A comprehensive approach to the patient with diabetes. <i>Osteopathic Family Physician</i> , 2013, 5, 51-57.	0.2	0
61	Evidence from randomized clinical trials demonstrating improved glycemic control with GLP-1 receptor agonists when used with other agents vs other combination therapy strategies. <i>Osteopathic Family Physician</i> , 2013, 5, 43-50.	0.2	0
62	GLP-1 receptor agonists or DPP-4 inhibitors: How to guide the clinician?. <i>Annales D'Endocrinologie</i> , 2013, 74, 515-522.	0.6	20
63	Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study. <i>Diabetes, Obesity and Metabolism</i> , 2013, 15, 204-212.	2.2	123
64	Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. <i>Diabetes, Obesity and Metabolism</i> , 2013, 15, 737-749.	2.2	178
65	Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Combination with Metformin. <i>Advances in Therapy</i> , 2013, 30, 337-353.	1.3	10
66	Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Type 2 diabetes. <i>Current Medical Research and Opinion</i> , 2013, 29, 1617-1626.	0.9	12
67	Physiologic and Weight-Focused Treatment Strategies for Managing Type 2 Diabetes Mellitus: The Metformin, Glucagon-Like Peptide-1 Receptor Agonist, and Insulin (MGI) Approach. <i>Postgraduate Medicine</i> , 2013, 125, 112-126.	0.9	13
68	Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. <i>BMJ Open</i> , 2013, 3, e001986.	0.8	243
69	GLP-1R agonist therapy for diabetes. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2013, 20, 87-97.	1.2	47
70	A patient-centred approach to treatment with incretin-based agents in patients with type 2 diabetes. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2013, 38, 181-189.	0.7	3
71	Incretin for the continuing treatment of secondary failure to metformin in Type 2 diabetes. <i>Diabetes Management</i> , 2013, 3, 323-331.	0.5	1
72	Liraglutide Achieves A1C Targets More often than Sitagliptin or Exenatide when Added to Metformin in Patients with Type 2 Diabetes and a Baseline A1C <8.0%. <i>Endocrine Practice</i> , 2013, 19, 64-72.	1.1	15
73	Evaluating the Short-Term Cost-Effectiveness of Liraglutide Versus Sitagliptin in Patients with Type 2 Diabetes Failing Metformin Monotherapy in the United States. <i>Journal of Managed Care Pharmacy</i> , 2013, 19, 237-246.	2.2	35
74	Risk of diarrhea in patients with type 2 diabetes mellitus treated with sitagliptin: a meta-analysis of 30 randomized clinical trials. <i>Drug Design, Development and Therapy</i> , 2014, 8, 2283.	2.0	5
75	Comparative effectiveness of liraglutide in the treatment of type 2 diabetes. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2014, 7, 107.	1.1	24
76	Systematic Review and Network Meta-analysis to Compare Dapagliflozin with other Diabetes Medications in Combination with Metformin for Adults with Type 2 Diabetes. <i>Internal Medicine: Open Access</i> , 2014, 01, .	0.0	0

#	ARTICLE	IF	CITATIONS
77	Managing Loss of Glycemic Control in Middle-Aged Patients With Diabetes: The Role of GLP-1 Receptor Agonists in Combination-Therapy Regimens. <i>Journal of Osteopathic Medicine</i> , 2014, 114, 14-21.	0.4	1
78	Adverse Effects of GLP-1 Receptor Agonists. <i>Review of Diabetic Studies</i> , 2014, 11, 202-230.	0.5	227
79	Three years of liraglutide treatment offers continuously optimal glycemic control in a pediatric patient with maturity-onset diabetes of the young type 3. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2014, 28, 327-31.	0.4	11
80	Efficacy and tolerability of GLP-1 agonists in patients with type 2 diabetes mellitus: an Indian perspective. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2014, 5, 159-165.	1.4	5
81	Use of glucagon-like peptide-1 receptor agonists and bone fractures: A meta-analysis of randomized clinical trials (0.8, 124).	0.8	124
82	GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?. <i>International Journal of Clinical Practice</i> , 2014, 68, 557-567.	0.8	89
83	Real-World Clinical and Economic Outcomes of Liraglutide Versus Sitagliptin in Patients with Type 2 Diabetes Mellitus in the United States. <i>Diabetes Therapy</i> , 2014, 5, 579-590.	1.2	18
84	Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagliptin. <i>Journal of Medical Economics</i> , 2014, 17, 658-669.	1.0	21
85	Improved real-world glycaemic outcomes with liraglutide versus other incretin-based therapies in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 819-826.	2.2	30
86	Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece. <i>BMC Health Services Research</i> , 2014, 14, 419.	0.9	19
87	Evidence-Based Practice Use of Incretin-Based Therapy in the Natural History of Diabetes. <i>Postgraduate Medicine</i> , 2014, 126, 66-84.	0.9	10
88	Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 289-297.	5.5	293
89	Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation. <i>British Journal of Pharmacology</i> , 2014, 171, 1114-1128.	2.7	60
90	Real-World Cost-Effectiveness: Lower Cost of Treating Patients to Glycemic Goal with Liraglutide versus Exenatide. <i>Advances in Therapy</i> , 2014, 31, 202-216.	1.3	20
91	Choosing Appropriate Glucagon-like Peptide 1 Receptor Agonists: A Patient-Centered Approach. <i>Diabetes Therapy</i> , 2014, 5, 333-340.	1.2	6
92	Incorporating Incretin-Based Therapies into Clinical Practice for Patients with Type 2 Diabetes. <i>Advances in Therapy</i> , 2014, 31, 289-317.	1.3	9
93	A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON). <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 636-644.	2.2	150
94	Effect of GLP-1 Mimetics on Blood Pressure and Relationship to Weight Loss and Glycemia Lowering: Results of a Systematic Meta-Analysis and Meta-Regression. <i>American Journal of Hypertension</i> , 2014, 27, 130-139.	1.0	116

#	ARTICLE	IF	CITATIONS
95	Insulin plus incretin agent combination therapy in type 2 diabetes: a systematic review. <i>Current Medical Research and Opinion</i> , 2014, 30, 431-445.	0.9	16
96	Sitagliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus. <i>Drugs</i> , 2014, 74, 223-242.	4.9	79
97	Liraglutide: A Review of Its Use in Adult Patients with Type 2 Diabetes Mellitus. <i>Drugs</i> , 2014, 74, 2161-2174.	4.9	42
98	Pancreatic Enzyme Supplementation Improves the Incretin Hormone Response and Attenuates Postprandial Glycemia in Adolescents With Cystic Fibrosis: A Randomized Crossover Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 2486-2493.	1.8	69
99	Composite endpoints in trials of type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 492-499.	2.2	24
100	Cost-Utility Analysis of Glucagon-Like Peptide-1 Agonists Compared with Dipeptidyl Peptidase-4 Inhibitors or Neutral Protamine Hagedorn Basal Insulin as Add-On to Metformin in Type 2 Diabetes in Sweden. <i>Diabetes Therapy</i> , 2014, 5, 591-607.	1.2	21
101	The Place of Dpp-4 Inhibitors in the Treatment Algorithm of Diabetes Type 2: A Systematic Review of Cost-Effectiveness Studies. <i>Value in Health</i> , 2014, 17, A347-A348.	0.1	0
102	Blood Pressure-Lowering Effects of Incretin-Based Diabetes Therapies. <i>Canadian Journal of Diabetes</i> , 2014, 38, 364-371.	0.4	35
103	Complementary Approaches to Improving Glucose Control—Insulin and Incretins. <i>The Diabetes Educator</i> , 2014, 40, 4S-26S.	2.6	0
105	Efficacité en pratique clinique courante des incrétino-mimétiques dans le traitement du diabète de type 2 : résultats d'une enquête nationale rétrospective au Royaume-Uni. <i>Medecine Des Maladies Metaboliques</i> , 2014, 8, 177-183.	0.1	1
106	Meta-Analysis of the Cardiovascular Outcomes with Dipeptidyl Peptidase 4 Inhibitors: Validation of the Current FDA Mandate. <i>American Journal of Cardiovascular Drugs</i> , 2014, 14, 191-207.	1.0	14
107	Liraglutide versus Sitagliptin in a 24-week, Multicenter, Open-label, Randomized, Parallel-group Study in Japanese Type 2 Diabetes Mellitus Patients Responding Inadequately to a Sulfonylurea and/or One or Two Other Oral Antidiabetic Drugs (JDDM 33). <i>Japanese Clinical Medicine</i> , 2014, 5, JCM.S16585.	1.9	6
108	Management of Type 2 diabetes with liraglutide. <i>Diabetes Management</i> , 2014, 4, 189-201.	0.5	1
109	Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD 1 and AWARD 3 clinical trials. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 896-903.	2.2	27
110	Potential Cardiovascular Effects of the Glucagon-like Peptide-1 Receptor Agonists. <i>Journal of Diabetes & Metabolism</i> , 2015, 06, .	0.2	2
111	Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide. <i>World Journal of Diabetes</i> , 2015, 6, 807.	1.3	62
112	Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor. <i>Clinical Pharmacokinetics</i> , 2015, 54, 1027-1041.	1.6	83
113	Add-On Treatment with Liraglutide Improves Glycemic Control in Patients with Type 2 Diabetes on Metformin Therapy. <i>Diabetes Technology and Therapeutics</i> , 2015, 17, 468-474.	2.4	15

#	ARTICLE	IF	CITATIONS
114	Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 and Metabolism, 2015, 17, 1056-1064.	2.2	89
115	Impact of Current and Emerging Glucose-Lowering Drugs on Body Weight in Type 2 Diabetes. Canadian Journal of Diabetes, 2015, 39, S148-S154.	0.4	26
116	Gastrointestinal Adverse Events of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. Diabetes Technology and Therapeutics, 2015, 17, 35-42.	2.4	99
117	A review of gliptins for 2014. Expert Opinion on Pharmacotherapy, 2015, 16, 43-62.	0.9	88
118	A multiplicity of targets: evaluating composite endpoint studies of the GLP-1 receptor agonists in type 2 diabetes. Current Medical Research and Opinion, 2015, 31, 125-135.	0.9	12
119	Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus. Therapeutic Advances in Endocrinology and Metabolism, 2015, 6, 3-18.	1.4	41
120	Effect of GLP-1 receptor agonists on waist circumference among type 2 diabetes patients: a systematic review and network meta-analysis. Endocrine, 2015, 48, 794-803.	1.1	31
121	Potential side effects to GLP-1 agonists: understanding their safety and tolerability. Expert Opinion on Drug Safety, 2015, 14, 207-218.	1.0	41
122	Mechanisms underlying weight loss and metabolic improvements in rodent models of bariatric surgery. Diabetologia, 2015, 58, 211-220.	2.9	54
123	Incretin-based therapies for obesity treatment. Metabolism: Clinical and Experimental, 2015, 64, 967-981.	1.5	31
124	Liraglutide for Type 2 diabetes and obesity: a 2015 update. Expert Review of Cardiovascular Therapy, 2015, 13, 753-767.	0.6	62
125	Cost-Effectiveness Analysis of Incretin Therapy for Type 2 Diabetes in Spain: 1.8Âmg Liraglutide Versus Sitagliptin. Diabetes Therapy, 2015, 6, 61-74.	1.2	24
126	The non-glycemic effects of incretin therapies on cardiovascular outcomes, cognitive function and bone health. Expert Review of Endocrinology and Metabolism, 2015, 10, 101-114.	1.2	6
128	Risk of bone fractures associated with glucagon-like peptide-1 receptor agonistsâ€™ treatment: a meta-analysis of randomized controlled trials. Endocrine, 2015, 48, 107-115.	1.1	143
129	Evaluating the Cost of Bringing People with Type 2 Diabetes Mellitus to Multiple Targets of Treatment in Canada. Clinical Therapeutics, 2015, 37, 1677-1688.	1.1	11
130	Evaluation of the effectiveness of liraglutide and sitagliptin in type 2 diabetes: a retrospective study in <sc>UK</sc> primary care. International Journal of Clinical Practice, 2015, 69, 281-291.	0.8	19
131	Systematic review and meta-analysis of efficacy and safety of combinational therapy with metformin and dipeptidyl peptidase-4 inhibitors. Saudi Pharmaceutical Journal, 2015, 23, 603-613.	1.2	6
132	A review of glycemic efficacy of liraglutide once daily in achieving glycated hemoglobin targets compared with exenatide twice daily, or sitagliptin once daily in the treatment of type 2 diabetes. Journal of King Abdulaziz University, Islamic Economics, 2016, 37, 834-842.	0.5	5

#	ARTICLE	IF	CITATIONS
133	<i>Cost-of-Illness</i> Study of Diabetes Mellitus: Focus on Patients with Type 2 Diabetes. Global & Regional Health Technology Assessment, 2016, 3, GRHTA.5000209.	0.2	2
134	Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists. Endocrinology and Metabolism, 2016, 31, 258.	1.3	36
135	Effects of dipeptidyl peptidase-4 inhibitors on blood pressure in patients with type 2 diabetes. Journal of Hypertension, 2016, 34, 167-175.	0.3	48
136	Clinical Effectiveness of Liraglutide vs Sitagliptin on Glycemic Control and Body Weight in Patients with Type 2 Diabetes: A Retrospective Assessment in Sweden. Diabetes Therapy, 2016, 7, 321-333.	1.2	7
137	Obviating much of the need for insulin therapy in type 2 diabetes mellitus: A re-assessment of insulin therapy's safety profile. Postgraduate Medicine, 2016, 128, 609-619.	0.9	17
138	Monitoring safety and use of old and new treatment options for type 2 diabetic patients: a two-year (2013-2016) analysis. Expert Opinion on Drug Safety, 2016, 15, 17-34.	1.0	6
139	Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial. Diabetes, Obesity and Metabolism, 2016, 18, 803-811.	2.2	23
140	Effect of glucagon-like peptide-1 on major cardiovascular outcomes in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. International Journal of Cardiology, 2016, 222, 957-962.	0.8	13
141	Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (<i>LIRA-SWITCH</i>): a randomized, double-blind, double-dummy, active-controlled 26-week trial. Diabetes, Obesity and Metabolism, 2016, 18, 1191-1198.	2.2	31
142	NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis. Science Translational Medicine, 2016, 8, 334ra51.	5.8	182
143	The efficacy and safety of liraglutide added to metformin in patients with diabetes: a meta-analysis of randomized controlled trials. Scientific Reports, 2016, 6, 32714.	1.6	13
144	Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial. Diabetes Care, 2016, 39, 1501-1509.	4.3	126
145	Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review. Diabetes Therapy, 2016, 7, 411-438.	1.2	66
146	Network meta-analysis accurately predicted the outcome of a subsequent randomised trial comparing once weekly dulaglutide 1.5 mg and once daily liraglutide 1.8 mg. International Journal of Clinical Practice, 2016, 70, 218-221.	0.8	6
147	Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes, Obesity and Metabolism, 2016, 18, 203-216.	2.2	322
148	Liraglutide vs. sitagliptin add-on to metformin treatment for type 2 diabetes mellitus: Short-term cost-per-controlled patient in Italy. Primary Care Diabetes, 2016, 10, 220-226.	0.9	5
149	Evaluation of the long-term cost-effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics, 2016, 19, 131-144.	1.0	16
150	Sitagliptin: A Review in Type 2 Diabetes. Drugs, 2017, 77, 209-224.	4.9	83

#	ARTICLE	IF	CITATIONS
151	Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: <sc>T</sc>he <sc>DURATIONâ€NEO</sc>â€2 randomized clinical study. Diabetes, Obesity and Metabolism, 2017, 19, 979-988.	2.2	38
152	Safety and efficacy of liraglutide treatment in Japanese type 2 diabetes patients after acute myocardial infarction: A non-randomized interventional pilot trial. Journal of Cardiology, 2017, 69, 511-517.	0.8	8
153	Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes and Endocrinology, the, 2017, 5, 341-354.	5.5	307
154	Efficacy and safety of liraglutide versus sitagliptin both in combination with metformin in patients with type 2 diabetes. Medicine (United States), 2017, 96, e8161.	0.4	20
155	The role of glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes. Journal of Translational Internal Medicine, 2017, 5, 79-89.	1.0	8
156	The place of DPP-4 inhibitors in the treatment algorithm of diabetes type 2: a systematic review of cost-effectiveness studies. European Journal of Health Economics, 2017, 18, 937-965.	1.4	13
157	Beneficial effect of lixisenatide after 76 weeks of treatment in patients with type 2 diabetes mellitus: A meta-analysis from the <sc>GetGoal</sc> programme. Diabetes, Obesity and Metabolism, 2017, 19, 248-256.	2.2	6
158	Cardiovascular effects of dipeptidyl peptidase-4 inhibitor in diabetic patients with and without established cardiovascular disease: a meta-analysis and systematic review. Postgraduate Medicine, 2017, 129, 205-215.	0.9	25
159	Interplay between bone and incretin hormones: A review. Morphologie, 2017, 101, 9-18.	0.5	11
160	Mechanism of lipid-lowering action of the dipeptidyl peptidase-4 inhibitor, anagliptin, in low-density lipoprotein receptor-deficient mice. Journal of Diabetes Investigation, 2017, 8, 155-160.	1.1	27
161	Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis. BMJ: British Medical Journal, 2017, 357, j2499.	2.4	52
162	Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2017, Volume 10, 123-139.	1.1	81
163	Efficacy and safety of alogliptin in a pediatric patient with maturity-onset diabetes of the young type 1. Clinical Pediatric Endocrinology, 2017, 26, 183-188.	0.4	5
164	Incretin-based therapy for the treatment of bone fragility in diabetes mellitus. Peptides, 2018, 100, 108-113.	1.2	9
165	Efficacy of glucagon-like peptide-1 receptor agonists compared to dipeptidyl peptidase-4 inhibitors for the management of type 2 diabetes: A meta-analysis of randomized clinical trials. Diabetes, Obesity and Metabolism, 2018, 20, 68-76.	2.2	32
166	Risk of dipeptidyl peptidase-4 (DPP-4) inhibitors on site-specific cancer: A systematic review and meta-analysis. Diabetes/Metabolism Research and Reviews, 2018, 34, e3004.	1.7	49
167	Dipeptidyl peptidase-4 inhibitors as preferable oral hypoglycemic agents in terms of treatment satisfaction: Results from a multicenter, 12-week, open label, randomized controlled study in Japan (PREFERENCE 4 study). Journal of Diabetes Investigation, 2018, 9, 137-145.	1.1	16
168	Cardiovascular Safety of Antihyperglycemic Agents: â€Do Good or Do No Harmâ€ Drugs, 2018, 78, 1567-1592.	4.9	8

#	ARTICLE	IF	CITATIONS
169	Liraglutide Treatment Reduces Endothelial Endoplasmic Reticulum Stress and Insulin Resistance in Patients With Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2018, 7, e009379.	1.6	34
170	Real-World Clinical Effectiveness and Cost Savings of Liraglutide Versus Sitagliptin in Treating Type 2 Diabetes for 1 and 2 Years. <i>Diabetes Therapy</i> , 2018, 9, 1279-1293.	1.2	7
171	Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 188-193.	2.2	33
172	GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials. <i>Endocrine</i> , 2019, 66, 157-165.	1.1	45
173	Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. <i>Diabetes Care</i> , 2019, 42, 1912-1920.	4.3	35
174	Risk of Malignant Neoplasia with Glucagon-Like Peptide-1 Receptor Agonist Treatment in Patients with Type 2 Diabetes: A Meta-Analysis. <i>Journal of Diabetes Research</i> , 2019, 2019, 1-10.	1.0	21
175	Cost-benefit comparison of liraglutide and sitagliptin in the treatment of type 2 diabetes in Thailand. <i>ClinicoEconomics and Outcomes Research</i> , 2019, Volume 11, 423-430.	0.7	2
176	Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force. <i>Diabetes Therapy</i> , 2019, 10, 1645-1717.	1.2	32
177	Safety and Efficacy of Weight Loss Pharmacotherapy in Persons Living with HIV: A Review of the Literature and Potential Drug-Drug Interactions with Antiretroviral Therapy. <i>Pharmacotherapy</i> , 2019, 39, 1204-1215.	1.2	10
178	Therapeutic Effects of Endogenous Incretin Hormones and Exogenous Incretin-Based Medications in Sepsis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5274-5284.	1.8	19
179	Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 528-539.	5.5	156
180	GLP-1 Receptor Agonists for Type 2 Diabetes and Their Role in Primary Care: An Australian Perspective. <i>Diabetes Therapy</i> , 2019, 10, 1205-1217.	1.2	6
181	Effect of sitagliptin and glimepiride on C-reactive protein (CRP) in overweight Type-2 diabetic patients. <i>Pakistan Journal of Medical Sciences</i> , 2019, 35, 383-387.	0.3	5
182	Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1466.	3.8	233
183	Trial design and baseline data for LIRA-PRIME: A randomized trial investigating the efficacy of liraglutide in controlling glycaemia in type 2 diabetes in a primary care setting. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1543-1550.	2.2	2
185	Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?. <i>Diabetes/Metabolism Research and Reviews</i> , 2019, 35, e3070.	1.7	161
186	Quality of Life, Glycemic Control, Safety and Tolerability Associated with Liraglutide or Insulin Initiation in Patients with Type 2 Diabetes in Germany: Results from the Prospective, Non-interventional LIBERTY Study. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2020, 128, 170-181.	0.6	6
187	Efficacy of newer agents in the glycaemic management of patients with type 2 diabetes. <i>Current Medical Research and Opinion</i> , 2020, 36, 209-211.	0.9	3

#	ARTICLE	IF	CITATIONS
188	Real-world Effectiveness of Liraglutide vs. Sitagliptin Among Older Patients with Type 2 Diabetes Enrolled in a Medicare Advantage Prescription Drug Plan: A Retrospective Observational Study. <i>Diabetes Therapy</i> , 2020, 11, 213-228.	1.2	1
189	Comparisons between dipeptidyl peptidase-4 inhibitors and other classes of hypoglycemic drugs using two distinct biomarkers of pancreatic beta-cell function: A meta-analysis. <i>PLoS ONE</i> , 2020, 15, e0236603.	1.1	2
190	Diabetes-Related Effectiveness and Cost of Liraglutide or Insulin in German Patients with Type 2 Diabetes: A 5-Year Retrospective Claims Analysis. <i>Diabetes Therapy</i> , 2020, 11, 2357-2370.	1.2	2
191	Major cardiovascular events, heart failure, and atrial fibrillation in patients treated with glucagon-like peptide-1 receptor agonists: An updated meta-analysis of randomized controlled trials. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 1106-1114.	1.1	49
192	Practical guidance for use of oral semaglutide in primary care: a narrative review. <i>Postgraduate Medicine</i> , 2020, 132, 687-696.	0.9	4
193	GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials. <i>Frontiers in Endocrinology</i> , 2020, 11, 178.	1.5	137
194	Gastrointestinal adverse events with insulin glargine/lixisenatide fixed-ratio combination versus glucagon-like peptide-1 receptor agonist in people with type 2 diabetes mellitus: A network meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 136-146.	2.2	12
195	Obstetrician-Gynecologists' Strategies for Patient Initiation and Maintenance of Antiobesity Treatment with Glucagon-Like Peptide-1 Receptor Agonists. <i>Journal of Women's Health</i> , 2021, 30, 1016-1027.	1.5	5
196	Weekly Semaglutide vs. Liraglutide Efficacy Profile: A Network Meta-Analysis. <i>Healthcare (Switzerland)</i> , 2021, 9, 1125.	1.0	8
197	Primary care management of type 2 diabetes: a comparison of the efficacy and safety of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. <i>Postgraduate Medicine</i> , 2021, 133, 1-11.	0.9	3
198	Pharmacological treatment of hyperglycemia in type 2 diabetes. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	102
199	Comparison of GLP-1 Analogues versus Sitagliptin in the Management of Type 2 Diabetes: Systematic Review and Meta-Analysis of Head-to-Head Studies. <i>PLoS ONE</i> , 2014, 9, e103798.	1.1	31
200	Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0154206.	1.1	22
201	The Multicenter, Open-Label, Observational LEAD-Ph Study: Real-World Safety and Effectiveness of Liraglutide in Filipino Participants with Type 2 Diabetes. <i>Journal of the ASEAN Federation of Endocrine Societies</i> , 2018, 33, 114-123.	0.1	2
202	Incretin Therapy – Present and Future. <i>Review of Diabetic Studies</i> , 2011, 8, 307-322.	0.5	24
203	Liraglutide effect and action in diabetes-In (LEAD-In): A prospective observational study assessing safety and effectiveness of liraglutide in patients with type 2 diabetes mellitus treated under routine clinical practice conditions in India. <i>Indian Journal of Endocrinology and Metabolism</i> , 2016, 20, 838.	0.2	6
204	Effects of Therapy with Basal Insulin Analogues Combined with GLP 1 Analogues and Metformin in the Treatment of Obese Patients with Poorly Regulated Postprandial Glycemia. <i>Medicinski Arhiv = Medical Archives = Archives De Médecine</i> , 2014, 68, 313.	0.4	3
205	Denosumab improves glucose parameters in patients with impaired glucose tolerance: a systematic review and meta-analysis. <i>Journal of Drug Assessment</i> , 2021, 10, 97-105.	1.1	5

#	ARTICLE	IF	CITATIONS
206	Focus on Incretin-Based Therapies for Patients with Type 2 Diabetes and Cardiovascular Disease. <i>Endocrine Practice</i> , 2011, 17, 13-19.	1.1	0
207	Focus on Incretin-Based Therapies for Elderly Patients with Type 2 Diabetes. <i>Endocrine Practice</i> , 2011, 17, 20-26.	1.1	0
208	Comparative Real World Effectiveness of Liraglutide versus Sitagliptin in Patients with Type 2 Diabetes as an Add-On to Metformin Monotherapy in the United States. <i>Internal Medicine: Open Access</i> , 2014, 01, .	0.0	1
209	The Difficulty of Diabetic Therapy: An Observational Retrospective Study from Actual Clinical Practice. <i>Advances in Pharmacoeconomics & Drug Safety</i> , 2016, 5, .	0.1	0
210	The Effect of Micro Element Levels in Drinking Water on Adolescent Body Composition. <i>Kafkas Journal of Medical Sciences</i> , 2017, 7, 91-96.	0.1	0
211	Addition of Metformin to Liraglutide, A GLP-1 Receptor Agonist, Improves Glycemic Control in Patients with Type 2 Diabetes Mellitus. <i>Journal of Diabetes and Obesity</i> , 2017, 4, 1-6.	0.2	0
212	Estimating the budget impact of innovative pharmacological treatments for patients with type 2 diabetes mellitus in Italy: the case of liraglutide (GLP-1).. , 2022, 12, .		2
213	Cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors as combination therapy with metformin in the treatment of type 2 diabetes mellitus without established cardiovascular disease in Colombia. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, , 1-10.	0.7	3
215	Diabetes: how to manage overweight and obesity in type 2 diabetes mellitus. <i>Drugs in Context</i> , 0, 11, 1-12.	1.0	3
216	Optimization of trial duration to predict long-term HbA1c change with therapy: A pharmacometrics simulation-based evaluation. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2022, 11, 1443-1457.	1.3	3
217	Possible Mechanisms and Molecular Signaling of Incretins against the Development of Type 2 Diabetes Mellitus. <i>Current Molecular Pharmacology</i> , 2023, 16, 448-464.	0.7	1
218	Is the steady-state concentration, duration of action, or molecular weight of GLP-1RA associated with cardiovascular and renal outcomes in type 2 diabetes?. <i>European Journal of Internal Medicine</i> , 2023, 109, 79-88.	1.0	0
219	Links between Metabolic Syndrome and Hypertension: The Relationship with the Current Antidiabetic Drugs. <i>Metabolites</i> , 2023, 13, 87.	1.3	6